Data for: Marrow Hypocellularity, but Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients with Morphologic Residual Disease

Published: 9 February 2018| Version 1 | DOI: 10.17632/fczyvxth6z.1
John Reagan,
Peter Quesenberry,
Matthew Quesenberry,
James Butera,
Adam Olszewski,
Thomas Ollila


Data set of outcomes based on day 14 bone marrow assessment.